Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureChristopher L. Bowlus, Gideon M. Hirschfield, Alejandra M. Villamil, Kris V. Kowdley, Hany Elbeshbeshy, Christophe Corpechot, Andreas E. Kremer, Palak J. Trivedi, Yiannis Kallis, Sook-Hyang Jeong, Kyung min Kwon, Victor de Ledinghen, Daria B. Crittenden, Cynthia Levy
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Primary biliary cholangitis
10.1016/s0140-6736(20)31607-x · 2020
The diagnosis and management of patients with primary biliary cholangitis
10.1016/j.jhep.2017.03.022 · 2017
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome
10.1016/j.jhep.2011.02.031 · 2011
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study
10.1053/j.gastro.2014.08.029 · 2014
Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis
10.1111/apt.70391 · 2026
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
10.1097/hep.0000000000000529 · 2024
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
10.14309/ajg.0000000000000557 · 2020
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
10.1016/j.jhep.2022.06.017 · 2022
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis
10.1002/hep.25599 · 2012
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
10.1016/j.cgh.2024.06.035 · 2024
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis
10.1016/j.jhep.2025.09.024 · 2026
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
10.1056/nejmoa2312100 · 2024
Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
10.1016/j.jbc.2022.102056 · 2022
Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators
10.3390/molecules29215189 · 2024
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
10.14309/ajg.0000000000003603 · 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
2025
Unresolved referenced work
Kept as external metadata until matched
Baveno VII - Renewing consensus in portal hypertension
10.1016/j.jhep.2021.12.022 · 2022
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
10.1016/j.cgh.2024.07.003 · 2024
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
2025
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
10.1016/j.cgh.2018.12.028 · 2019
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
10.1111/apt.15533 · 2019
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
10.1056/nejmoa1714519 · 2018
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
10.1016/j.cgh.2024.10.020 · 2025
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
2026
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
10.14309/ajg.0000000000003603 · 2025
No additional external references are available.